52-year-old woman with fever, palate ulcer, and crackles
A 52-year-old woman with plaque psoriasis on adalimumab presents with 3 weeks of fever, dry cough, and fatigue. She works as a warehouse clerk in southern Indiana and initially blamed overtime shifts for her symptoms. Temperature is 38.8 C (101.8 F), pulse is 106/min, blood pressure is 94/58 mm Hg, and oxygen saturation is 88% on ambient air. Physical examination reveals a hard palate ulcer, splenomegaly, and diffuse crackles. Laboratory testing shows hemoglobin 8.3 g/dL, leukocytes 2,400/mm3, platelets 64,000/mm3, creatinine 1.7 mg/dL (baseline 0.8 mg/dL), and lactate dehydrogenase 1,380 U/L. Chest radiography demonstrates diffuse reticulonodular opacities. Peripheral blood buffy coat examination reveals 2- to 4-µm oval budding yeast inside monocytes. Which of the following is the most appropriate initial treatment?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
A
Explanation
Clinical Pearl:
Moderately severe to severe disseminated histoplasmosis requires initial induction therapy with intravenous liposomal amphotericin B rather than oral azoles. Echinocandins lack meaningful activity against dimorphic fungi because the yeast-phase cell wall contains predominantly alpha-glucans.
Explanation:
This immunosuppressed patient on tumor necrosis factor alpha inhibitor therapy presents with severe disseminated histoplasmosis, confirmed by the presence of 2- to 4-µm oval narrow-based budding yeasts within monocytes on buffy coat examination alongside fevers, mucosal ulceration, splenomegaly, pancytopenia, and diffuse reticulonodular pulmonary opacities. Current infectious disease society guidance establishes intravenous liposomal amphotericin B as the mandatory initial induction regimen for moderately severe to severe disseminated disease, defined by life-threatening features including room-air hypoxemia, hypotension, acute kidney injury, and marked cytopenias. Oral itraconazole solution therapy is indicated exclusively for mild to moderate histoplasmosis or as step-down consolidation after clinical stabilization with amphotericin B, and its delayed time to steady-state serum concentrations renders it ineffective for acute severe disease. Intravenous micafungin infusion therapy lacks efficacy because dimorphic fungal cell walls are composed predominantly of alpha-glucans rather than beta-1,3-glucans, conferring intrinsic resistance to all echinocandins. Intravenous fluconazole infusion therapy has substantially lower fungicidal activity against Histoplasma species, with demonstrated clinical failure and high rates of acquired resistance, relegating it to second-line salvage when itraconazole cannot be used. Intravenous voriconazole infusion therapy serves as primary therapy for invasive mold infections such as aspergillosis, but it lacks established efficacy as primary induction therapy for severe disseminated histoplasmosis.
See you tomorrow morning!